-
MDA taps Bridgebio funding to improve LGMD care coordination
Bridgebio is providing $100,000 to the Muscular Dystrophy Association (MDA) to advance projects aimed at
-
RegenXBio announces positive topline results from pivotal Phase 3 microdystrophin gene therapy trial
RegenXBio shared positive topline results from their pivotal Phase 3 AFFINITY DUCHENNE study of RGX-202








